COMPARISON OF PET/CT AND MRI IN LYMPH NOE INVOLVEMENT AND PELVIC EXTRATERINE DISEASE DETECTION OF ENDOMETRIAL CANCER: PRESURGICAL STAGING

V Garcia Pineda1, I Cristóbol, M Gracia, M Coronado, J Zapardiel, J Siegrist, MD Diestro, Y Pérez Martínez, A Hernández, La Paz University Hospital, Gynaecological Oncology, Madrid, Spain

10.1136/ijgc-2021-ESGO.650

Introduction/Background Pre-surgical staging in endometrial cancer is crucial for planning surgical treatment and adjuvant therapy of the disease. The aim of the present study is to determine the diagnostic accuracy of PET/CT and MRI in the detection of pelvic extraterine disease and lymph node involvement.

Methodology An ambispective descriptive study was conducted including patients diagnosed with early stage high-risk endometrial cancer or advanced stage endometrial cancer between January 2011 and July 2021 in our Institution. In all cases included, a pre-surgical study with PET/CT and MRI was performed and lymph node debulking or lymph node staging with pelvic and para-aortic lymphadenectomy was carried out.

Finally, we compared the sensitivity, specificity, positive predictive value, and negative predictive value for the detection of adenopathies and/or extraterine pelvic disease detected by PET/CT and MRI. All statistical analysis were performed using the software SPSS Statistics v.24.0 (IBM Corp., Armonk, NY, USA).

Results The results after final statistical analysis will be available when the prospective data collection has been finalised.

Conclusion The hypothesis we plan to confirm is that MRI is not superior to PET/CT in the detection of lymph node involvement and can be omitted in the pre-surgical study of early stages of high-risk endometrial cancer. However, in advanced stages, MRI may be useful given its greater ability to delineate the pelvic extension of the primary tumor.

EARLY STAGE, LOW GRADE ENDOMETRIAL ADENOCARCINOMA IN REPRODUCTIVE AGED WOMEN: PILOT TESTING OF A PATIENT DECISION AID

A Roman1, M Peate, Y Jayasinghe, OM McNally, The Royal Women’s Hospital, Melbourne Australia, Gynaecology Oncology, Parkville, Australia; 2The Royal Women’s Hospital, Melbourne Australia, The University of Melbourne, Department of Obstetrics and Gynaecology, Parkville, Australia; 3The Royal Women’s Hospital, Melbourne Australia, The Royal Children’s Hospital, Department of Obstetrics and Gynaecology, Parkville, Australia; 4The Royal Women’s Hospital, Melbourne Australia, Peter MacCallum Cancer Centre, Melbourne Australia, Director of Gynaecology Oncology, Parkville, Australia

10.1136/ijgc-2021-ESGO.651

Introduction/Background Endometrial adenocarcinoma (EAC) is rare in reproductive aged women. Patient perspectives of treatment in this cohort have highlighted unmet needs in information provision and decisional conflict around standard surgical treatment or treatment with progestins, and implications for fertility and oncological outcomes. Decision aids have been used to support information provision and clinical decision-making. Patients exposed to decision aids are more knowledgeable, better informed and clearer about their values. We developed and pilot tested a decision aid for reproductive aged women with low grade, early stage EAC.

Disclosures of our latest data using sentinel lymph node (SLN) for staging all endometrial cancers

J Cespedes Manterola1, R Ruiz, I Jaunarena, M Gorostidi, P Cobas, A Lekuona. Donostia Unibertsitate Ospitalea, Ginecologia y Obstetricia, Donostia, Spain

10.1136/ijgc-2021-ESGO.652

Introduction/Background SLN biopsy can be considered for staging in patients with low-risk/intermediate-risk disease and it is an acceptable alternative to lymphadenectomy for LN staging in stage I/II. LN staging should be performed in patients with high-intermediate-risk/high-risk disease. Four prospective cohort trials have shown high sensitivity to detect pelvic LN metastases and a high negative predictive value applying a SLN algorithm in high-risk/high-grade endometrial carcinomas. Our aim is present our prospective results in endometrial cancer applying new ESGO/ESMO/ESTRO recommendations for staging all endometrial cancers comparing them with our previous 333 patients data.

Methodology A prospective observational study is being conducted since 1 January 2021 with patients that undergo laparoscopic surgery for endometrial cancer at our institution. We perform only SLN biopsy with dual cervical and fundal indocyanine green injection in all endometrial cancers. All
SLNs were processed with an ultrastaging technique. Between 26 June 2014 and 31 December 2019 with 333 patients we applied the previous treatment algorithms. Between January and 30 August 2021 we did only SLN in 45 patients.

**Results**
Comparison of the results between the ancient and the new serie (ancient/new): Detection rate 94%/97.7% overall for SLNs; 91.3%/97.7% overall for pelvic SLNs; 70.5%/88.8% for bilateral SLNs; 68.1%/88.8% for paraaortic SLNs, and 2.9%/0% for isolated paraaortic SLNs.

Macrometastasis 18%/60% patients and microdisease 17.6%/8.8% patients, overall rate of LN involvement 16.2%/11%. Isolated Aortic metastases 4.2%/2.2% (14/333–1/45). Assuming the results of the ancient serie there was one false/negative (negative SLN with positive lymphadenectomy). Our sensitivity of detection was 98.3% (95% CI 91–99.7), specificity 100% (95% CI 98.5–100), negative predictive value 99.6% (95% CI 97.8–99.9), and positive predictive value 100% (95% CI 93.8–100).

**Conclusion**
SLN biopsy is an acceptable alternative to systematic lymphadenectomy for LN staging in stage I/II. We avoid aortic metastases. Isolated Aortic metastases in endometrial cancer is an acceptable possibility given the high remission rate. Additionally, this technique allows a high rate of aortic detection, identifying a non-negligible percentage of isolated aortic metastases. Isolated Aortic metastases in endometrial cancer are and we should not give up actively looking for them.

---

**Introduction/Background**
Diagnostic efficacy of sentinel lymph node (SLN) biopsy is proven in many studies in terms of the detection of lymphatic spread in endometrial cancer. However, there are limited data about the effect of SLN biopsy only on survival. The aim of this study was to investigate whether SLN biopsy only compromises oncologic outcomes compared to systematic lymphadenectomy in a large cohort.

**Methodology**
In this multicentric study, records of 564 endometrial cancer patients who underwent surgical staging with either sentinel lymph node biopsy alone or sentinel lymph node biopsy followed by systematic lymphadenectomy with at least 6 months of follow-up time were retrospectively reviewed. The impact of type of lymphadenectomy and histopathologic factors on recurrence, disease-free survival (DFS) and overall survival (OS) were assessed. DFS and OS rates were calculated using Kaplan-Meier method and log-rank test was used to calculate statistical significance between the groups. Cox univariate and multivariate analyses were used to identify prognostic factors for DFS and OS.

**Result(s)**
Median follow up time was 28 months (range: 6–130) and 14 (2.5%) of the 21 (3.7%) deaths were due to the disease. 2- and 3-year OS were 98.2% and 97%, respectively. Median time to recurrence was 12.5 months (range: 3-30). Sites of the 42 (7.4%) recurrences were as follows: 12 (28.6%) locoregional, 19 (45.2%) distant, 3 (7.1%) nodal and 8 (19%) more than one site. 2- and 3-year DFS were 93.1% and 92.6%, respectively. While non-endometrioid subtypes (p=0.048), grade 3 histology (p<0.001) and presence of lymphovascular space invasion (LVS) (p<0.001) were found as independent prognostic factors for decreased DFS, age (p=0.017) and tumor size (p=0.041) were independent factors for shorter OS. Type of lymphadenectomy was not a prognostic factor lymphatic recurrence, DFS and OS.

**Conclusion**
Our study showed that removal of only SLNs was not associated with worse survival compared to systematic lymphadenectomy in endometrial cancer patients. Nodal recurrence rate was also similar between the groups.